Clinical Trials Browser

Completed × mirvetuximab soravtansine × Breast × Clear all

NCT02996825 2024-04-02

Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer

Phase 1 Completed

BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT03106077 2020-12-02

Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer

Phase 2 Completed

96 enrolled 8 charts

Triple Negative Breast Neoplasms